Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trajan Group Holdings's ROE % for the quarter that ended in Dec. 2025 was -0.86%. Trajan Group Holdings's PB Ratio for the quarter that ended in Dec. 2025 was 0.94.
Trajan Group Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -0.91%.
Trajan Group Holdings ROE % Adjusted to Book Value Related Terms
Trajan Group Holdings ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Trajan Group Holdings's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trajan Group Holdings ROE % Adjusted to Book Value Chart
FRA:Z0M vs ISRG, BDX, MDLN: ROE % Adjusted to Book Value Comparison
For the Medical Instruments & Supplies subindustry, Trajan Group Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trajan Group Holdings ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trajan Group Holdings's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Trajan Group Holdings's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -0.91% mean?
Trajan Group Holdings (FRA:Z0M) has a ROE % Adjusted to Book Value of -0.91% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Trajan Group Holdings and its competitors.
Is Trajan Group Holdings' ROE % Adjusted to Book Value too high?
Trajan Group Holdings' current ROE % Adjusted to Book Value is -0.91%. Overall, Trajan Group Holdings has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trajan Group Holdings' ROE % Adjusted to Book Value compare to ISRG and BDX?
Trajan Group Holdings' ROE % Adjusted to Book Value of -0.91% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Trajan Group Holdings and its competitors. Trajan Group Holdings's current ROE % Adjusted to Book Value is -0.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trajan Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Trajan Group Holdings (FRA:Z0M) is currently considered Possible Value Trap. The stock's GF Value™ is €0.62, compared to a current price of €0.17 — trading 73.1% below its estimated fair value. The current ROE % Adjusted to Book Value is -0.91%. Trajan Group Holdings' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Trajan Group Holdings (FRA:Z0M), the current ROE % Adjusted to Book Value is -0.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trajan Group Holdings (FRA:Z0M) Overvalued in 2026?
Based on GuruFocus' analysis, Trajan Group Holdings stock appears to be undervalued.
The current stock price of €0.17 is trading 73.1% below its estimated GF Value™ of €0.62.
GuruFocus considers Trajan Group Holdings to be Possible Value Trap.
Key valuation signals for FRA:Z0M:
ROE % Adjusted to Book Value: -0.91%
GF Value™: €0.62 vs. price of €0.17 (73.1% below fair value)
No single metric tells the full story. See the FRA:Z0M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trajan Group Holdings Ltd is a developer and manufacturer of analytical and life sciences products and devices, seeking to enrich human well-being through scientific measurement. Its current portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Group now reports in three operating segments: Components and Consumables, Capital Equipment and Disruptive Technologies. Key revenue is generated from Components and consumables, which include parts, supplies, components, and consumable products worldwide. The Group operates in Asia (Malaysia, Japan and Australia and New Zealand (ANZ)), USA and Europe, Middle East, Africa, and India (EMEA).
23GF Score
Get the complete analysis for FRA:Z0M
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Z0M has been successfully added to your 
